A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Trial Profile

A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Belinostat (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BELIEF; Belinostat PTCL
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2015 According to Onxeo media release, results has been published in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology.
    • 23 Jun 2015 Results published in the Onxeo Media Release.
    • 07 Jul 2014 According to a Spectrum Pharmaceuticals media release, the US FDA granted accelerated approval to belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma based on this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top